TY  - JOUR
PY  - 2024//
TI  - Adjunctive duration-doubled transcranial direct current stimulation for the treatment of depressive patients with suicidal ideation: study protocol for a double-blind, randomized, sham-controlled trial
JO  - Trials
A1  - Chen, Yiming
A1  - Lyu, Dongbin
A1  - Wang, Fan
A1  - Huang, Qinte
A1  - Yang, Weichieh
A1  - Zhang, Mengke
A1  - Wei, Zheyi
A1  - Shi, Shuxiang
A1  - Kong, Shuqi
A1  - Chen, Shentse
A1  - He, Shuang
A1  - Yang, Vivien
A1  - Fang, Yiru
A1  - Douiri, Abdel
A1  - Hong, Wu
SP  - e15
EP  - e15
VL  - 25
IS  - 1
N2  - BACKGROUND: The problem of suicide has become increasingly common in individuals with major depressive disorder (MDD). Transcranial direct current stimulation (tDCS) is an effective treatment for MDD with 2 milliamperes (mA) for at least 30 min per day for 2 weeks. This study aims to investigate the efficacy of daily duration-doubled tDCS as an adjunctive intervention for rapidly reducing suicidal ideation and improving depression in MDD patients. <br><br>METHODS: In this double-blind, randomized, sham-controlled study, 76 MDD patients with suicidal ideation are randomly assigned to either active (n=38) or sham (n=38) tDCS group. The anode and cathode are placed over the scalp areas corresponding to left and right dorsolateral prefrontal cortex (DLPFC), respectively, and each stimulation lasts for 60 min. The primary outcome is defined as change of Beck Scale for Suicide Ideation (BSI) after 5 and 10 sessions. The change of other clinical assessments, blood biomarkers related to suicidal ideation and depressive sumptoms are defined as secondary outcomes. Blood biomarkers related to suicidal ideation are collected at baseline and after 10 sessions. <br><br>DISCUSSION: This study suggests the adjunctive duration-doubled tDCS might be a novel method to rapidly reduce suicidal ideation and improve depressive symptom. The variation of biomarkers could be potential predictive models of suicide risk. TRIAL REGISTRATION: The trial protocol is registered with ClinicalTrials.gov under protocol registration number NCT05555927. Registered on September 25, 2022.<p />  <p>Language: en</p>
LA  - en
SN  - 1745-6215
UR  - http://dx.doi.org/10.1186/s13063-023-07858-0
ID  - ref1
ER  -